Chester County News and Community Website
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) announced its financial results for the third quarter ending September 30, 2024, following the acquisition of assets from Endo International plc earlier this …
Endo, Inc. Reports Third-Quarter 2024 Financial Results Amid Strategic Developments Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) is expected to release its third-quarter 2024 financial results on November 5, 2024, before the market opens. The senior management team will conduct …
Join Endo, Inc.’s Q3 2024 Financial Results Call: Mark Your Calendar! Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has unveiled promising data from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in treating plantar fibromatosis, presented at the American Orthopaedic …
Endo, Inc. Highlights Promising Study Results for Plantar Fibromatosis Treatment Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced a significant leadership change as Blaise Coleman steps down from his roles as President, CEO, and Board member, effective August 29, …
Endo, Inc. Initiates CEO Transition and Strategic Search Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) recently reported its financial results for the second-quarter ending June 30, 2024, marking a significant phase in its growth strategy. Following its acquisition …
Endo, Inc. Reports Strong Second-Quarter 2024 Financial Performance Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) will release its second quarter 2024 financial results on August 27, 2024, before the market opens. The company’s senior management team will host …
Endo to Announce Q2 2024 Financial Results Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has released its annual Corporate Responsibility Report, showcasing the strides made by Endo International plc (“EIP”) in 2023. This report highlights the company’s …
Endo, Inc. Publishes 2023 Corporate Responsibility Report Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced a voluntary recall of one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. The recall affects tablets that may …
Endo Recalls Mislabelled Clonazepam Tablets Due to Overdose Risks Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has introduced a new generic version of the kidney stone medication, THIOLA EC®. The new drug, tiopronin delayed-release tablets, aims to provide a …
Endo Launches Generic Kidney Stone Medication Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has taken a significant step towards listing its shares on the New York Stock Exchange (NYSE) by filing a registration statement with the …
Endo, Inc. Files for NYSE Listing Amid Growth Strategy Read More